FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Solid Tumor, Adult
Interventions: DRUG: FT516|DRUG: Avelumab|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: IL-2
Sponsor: Fate Therapeutics